Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patient Basis

Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest’s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe.

More: continued here

Filed under: Cancer on June 30th, 2009